Dosage and administration
Typical daily dose: 30 - 50 mg once or twice a day.
Side effects
Side effects occur in approximately 12% of patients and are characterised by moderate headaches, insomnia, fatigue and allergic reactions.
Overdose
Сonsuming too much might result in an increase in potential side effects.
Country of Manufacture: Russia
1 Month Course is 4 boxes: 120 pills x 50mg
Unlike its younger brother Phenibut, Picamilon was ironically synthesised in the USSR for common people and not for cosmonauts.
This compound is based on a synthetic combination of GABA and niacin, with the former being responsible for reducing neuronal excitability and the latter acting as a strong vasodilator.
Its effects are similar to those of Phenibut as both drugs reduce anxiety and improve mood. However, unlike Phenibut, Picamilon has a much stronger impact on the energy metabolism in the brain because it stimulates consumption of oxygen and glucose by the neuronal tissue.
Similar to Phenibut Picamilon should be taken for a period of maximum 3 weeks and has the capacity to cause withdrawal syndrome if abused.
Picamilon can be used to treat the following symptoms and conditions:
- Cerebrovascular diseases
- Migraine
- Asthenic disorders (lack of energy)
- Depressions
- Alcohol withdrawal syndrome
One pack of Picamilon ® contains 30 pills, each 30 or 50 Mg of active ingredient, which is sufficient for approximately 15 - 30 days of administration.
Country of Manufacture: Russia
Availability: in stock
The product is available in different sizes. You can save by choosing a larger size.
- Voznesenskii et al (1989) Comparative study of the effect of picamilone and piracetam on learning in rats in a radial maze https://www.unboundmedicine.com/medline/citation/2806520/
- I Sapegin, A Beketov (1993) The effect of pikamilon and fenibut on the blood supply of the brain at rest and under gravitational exposures https://www.ncbi.nlm.nih.gov/pubmed/8324468
- Shyman’kyi et al (2002) Oxidative stress correction by nicotinamide and nicotynol-GABA in diabetic neuropathy https://www.ncbi.nlm.nih.gov/pubmed/12916162
- Kuchmerovs’ka et al (2003) State of GABA-benzodiazepine receptor complex in diabetic neuropathy: effect of nicotinamide and nicotinoyl-GABA https://www.ncbi.nlm.nih.gov/pubmed/14577176
- Silkina et al (2005) Gabaergic mechanism of cerebrovascular and neuroprotective effects of afobazole and picamilon https://www.ncbi.nlm.nih.gov/pubmed/15786959
- Likhodeev et al (2009) Effects of aminalon, fenibut, and picamilon on the typological parameters of cerebral hemodynamics in swimmers with dysadaptation syndrome https://www.ncbi.nlm.nih.gov/pubmed/19803364
- Avula et al (2016) Identification and quantification of vinpocetine and picamilon in dietary supplements sold in the United States https://www.ncbi.nlm.nih.gov/pubmed/26426301